Wedbush Equities Analysts Reduce Earnings Estimates for DNTH

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Wedbush dropped their Q1 2025 earnings per share estimates for shares of Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.74) per share for the quarter, down from their prior estimate of ($0.62). Wedbush currently has a "Outperform" rating and a $36.00 target price on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. Wedbush also issued estimates for Dianthus Therapeutics' Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($3.11) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($3.38) EPS, FY2028 earnings at ($2.75) EPS and FY2029 earnings at $1.79 EPS.

A number of other equities research analysts have also issued reports on DNTH. Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a "buy" rating on the stock. Finally, Guggenheim reaffirmed a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $52.14.

Remove Ads

Dianthus Therapeutics Price Performance

Shares of DNTH traded down $1.23 during midday trading on Friday, reaching $20.74. The stock had a trading volume of 269,726 shares, compared to its average volume of 237,512. Dianthus Therapeutics has a 52 week low of $18.13 and a 52 week high of $33.77. The firm's 50 day moving average price is $22.44 and its 200-day moving average price is $24.76. The company has a market capitalization of $613.84 million, a P/E ratio of -8.30 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently made changes to their positions in the business. Woodline Partners LP raised its holdings in Dianthus Therapeutics by 20.0% in the 4th quarter. Woodline Partners LP now owns 300,504 shares of the company's stock valued at $6,551,000 after acquiring an additional 50,000 shares in the last quarter. Vestal Point Capital LP raised its holdings in Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after acquiring an additional 680,000 shares in the last quarter. Octagon Capital Advisors LP raised its holdings in Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after acquiring an additional 363,500 shares in the last quarter. Millennium Management LLC raised its holdings in Dianthus Therapeutics by 160.2% in the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company's stock valued at $1,972,000 after acquiring an additional 55,682 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in Dianthus Therapeutics by 14.4% in the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock valued at $23,607,000 after acquiring an additional 136,314 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.